Drug Trial Radar · NCT05853367
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Jul 6, 2023
Primary completion
Jun 24, 2028
Study completion Jun 24, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Conditions
- Metastatic Solid Tumors
- Advanced Solid Tumors
Interventions
MK-0472Drug
Oral Administration
PembrolizumabBiological
IV infusion
MK-1084Drug
Oral Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose Limiting Toxicity (DLT) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 60 months
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 60 months
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
Northwestern Memorial Hospital ( Site 0002)
Chicago, Illinois
The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
Louisville, Kentucky
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey ( Site 0005)
New Brunswick, New Jersey
Princess Margaret Cancer Centre ( Site 0101)
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)
Montreal, Quebec, Canada
Département clinique de médecine de laboratoire du CHUM ( Site 0104)
Montreal, Quebec, Canada
Centro de Estudios Clínicos SAGA ( Site 0701)
Santiago, Region M. de Santiago, Chile
Fundacion Arturo Lopez Perez ( Site 0700)
Santiago, Region M. de Santiago, Chile
Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0702)
Santiago, Region M. de Santiago, Chile
Rambam Health Care Campus ( Site 0304)
Haifa, Israel
Shaare Zedek Medical Center ( Site 0303)
Jerusalem, Israel
Rabin Medical Center ( Site 0301)
Petah Tikva, Israel
Sheba Medical Center ( Site 0300)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0302)
Tel Aviv, Israel
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne ( Site 0400)
Gdansk, Pomeranian Voivodeship, Poland
Hospital Universitari Vall d'Hebron ( Site 0500)
Barcelona, Spain
Hospital Virgen del Rocio ( Site 0503)
Seville, Spain
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 0501)
L'Hospitalet de Llobregat, Catalonia, Spain
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0504)
Madrid, Madrid, Comunidad de, Spain
Hôpitaux Universitaires de Genève (HUG) ( Site 0202)
Geneva, Canton of Geneva, Switzerland
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201)
Sankt Gallen, Canton of St. Gallen, Switzerland
Ospedale Regionale Bellinzona e Valli ( Site 0200)
Bellinzona, Canton Ticino, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.